XPH
State Street SPDR S&P Pharmaceuticals ETF·ARCA
--
--(--)
--
--(--)
Key Stats
Assets Under Management
311.88MUSD
Fund Flows (1Y)
88.71MUSD
Dividend Yield
0.81%
Discount/Premium to NAV
0.14%
Shares Outstanding
5.30M
Expense Ratio
0.35%
About State Street SPDR S&P Pharmaceuticals ETF
Issuer
State Street Global Advisors
Brand
SPDR
Inception Date
Jun 19, 2006
Structure
Open-Ended Fund
Index Tracked
S&P Pharmaceuticals Select Industry Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
SSgA Funds Management, Inc.
Distributor
State Street Corp. (Fund Distributor)
XPH offers equal-weighted exposure to a narrow selection of US pharmaceutical companies, stretching across all market caps. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. The fund also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. Overall, XPH is a solid way to capture a less concentrated version of the pharma market. The index is rebalanced quarterly.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharmaceuticals
Strategy
Equal
Geography
U.S.
Weighting Scheme
Equal
Selection Criteria
Market cap
Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Holdings
Symbol
Ratio
DFTX
Definium
2.53%
LQDA
Liquidia
2.50%
MBX
MBX Biosciences
2.45%
AXSM
Axsome Therapeutics
2.29%
VTRS
Viatris
2.28%
MRK
Merck
2.23%
Symbol
Ratio
EWTX
Edgewise
2.21%
AMRX
Amneal
2.18%
OGN
Organon
2.13%
ELAN
Elanco Animal Health
2.11%
Top 10 Weight 22.92%
10 Total Holdings
See all holdings
Related Funds
Seasonals
Volume Profile
Trade Flow Insight
Community Forum
Loading...
Related News
No articles available
You can ask Aime
No Data
